Solutions to Enable Regional Genomic Medicine eConsult Services (R43/R44 Clinical Trial Optional)
ID: 351749Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/351749

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-106.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity for small businesses through the Solutions to Enable Regional Genomic Medicine eConsult Services (R43/R44 Clinical Trial Optional) grant. This initiative aims to support the development of innovative solutions that enhance clinician-to-clinician consultations in genomic medicine, particularly in underserved areas, by overcoming barriers to establishing regional eConsult services. Eligible applicants can request funding of up to $400,000 for Phase I and $2.15 million for Phase II, with a submission deadline of May 30, 2024. Interested parties can find more information and contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-106.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-106-Full-Announcement.html
    PAR-24-106.html
    The National Institutes of Health (NIH), through the National Human Genome Research Institute (NHGRI), is soliciting applications for Small Business Innovation Research (SBIR) grants aimed at developing innovative solutions for regional genomic medicine electronic consult (eConsult) services. This funding opportunity focuses on small businesses delivering products or services that enhance clinician-to-clinician consultations regarding genomic medicine, particularly in underserved areas. Key funding parameters include Phase I and Phase II applications, with budget requests up to $400,000 for Phase I and $2.15 million for Phase II. The initiative seeks to overcome barriers faced in the establishment of regional eConsult services; solutions could involve technology to integrate diverse electronic health record (EHR) systems, AI for managing consultations, or educational resources for healthcare providers. A pre-application webinar is scheduled for February 6, 2024, with submission deadlines starting from April 30, 2024. Applicants must meet strict eligibility criteria, including remaining a U.S. small business and adhering to NIH data sharing policies. Overall, this funding opportunity aims to improve access to genomic expertise and ensure equitable healthcare delivery across different regions.
    Similar Opportunities
    Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Required) to support early-career scientists transitioning into entrepreneurial roles within small businesses. This funding opportunity aims to facilitate the career development of investigators by providing entrepreneurial training, mentorship, and support for research and development projects that align with NIH's mission to improve health. Eligible small business concerns (SBCs) can apply for Phase I and Fast-Track grants, with funding amounts typically reaching $306,872 for Phase I and $2,045,816 for Phase II awards. Applications will be accepted starting August 5, 2024, with a closing date of April 5, 2027. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-134.html.
    NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)" aimed at supporting Small Business Concerns (SBCs) in conducting investigator-initiated exploratory clinical trials related to neurological disorders. This initiative encourages applications for Phase I and II studies focusing on drugs, biologics, devices, and therapies that align with the mission of the National Institute of Neurological Disorders and Stroke (NINDS), emphasizing the inclusion of a Plan for Enhancing Diverse Perspectives (PEDP) to foster innovation. The maximum funding amounts are $295,924 for Phase I and $1,972,828 for Phase II projects, with applications required to demonstrate readiness for eventual FDA regulatory approval. Interested applicants can begin submitting proposals on December 5, 2023, with the application deadline set for September 5, 2026; for further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), in collaboration with the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA), has announced the PHS 2024-2 Omnibus Solicitation for Small Business Innovation Research (SBIR) Grant Applications. This funding opportunity invites eligible U.S. small businesses to submit applications for Phase I, Phase II, Fast-Track, and Direct to Phase II projects that align with the research missions of the NIH, CDC, and FDA, with a focus on stimulating technological innovation and commercialization of federal R&D investments. Notably, applications must not include clinical trials, and funding levels are capped at $306,872 for Phase I and up to $2,045,816 for Phase II, with a submission deadline of April 5, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (U43/U44 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for small businesses to develop novel extracellular vesicle (EV)-based therapeutic platforms aimed at regenerative medicine through a cooperative agreement. The primary objective is to support the production, manufacturing, and application of EVs for tissue and organ repair, with a focus on utilizing stem cells for EV generation and ensuring GMP-compliant production. This initiative is critical for advancing therapeutic technologies in regenerative medicine, with funding amounts capped at $295,924 for Phase I and $1,972,828 for Phase II grants, while clinical trials are not permitted under this opportunity. Interested applicants must adhere to strict submission guidelines and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries, with the application deadline set for June 6, 2025.
    Addressing Health Inequities in Clinical Diagnostics (R43/R44 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Addressing Health Inequities in Clinical Diagnostics" under the Small Business Innovation Research (SBIR) program (R43/R44). This initiative invites Small Business Concerns (SBCs) to develop improved clinical diagnostics that address health disparities caused by existing clinical laboratory assays and point-of-care devices, particularly those that do not adequately consider diverse patient populations. The program aims to foster advancements that enhance health outcomes for historically underrepresented groups by encouraging applicants to identify specific disparities and propose innovative solutions. Applications will be accepted starting March 5, 2024, with a close date of January 5, 2027. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-158.html.
    PHS 2024-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) have announced the PHS 2024-2 Omnibus Solicitation for Small Business Innovation Research (SBIR) grant applications, specifically requiring clinical trials. This funding opportunity is aimed at U.S. small businesses with the necessary research capabilities to contribute to the missions of the NIH and CDC, encouraging innovation and the commercial viability of health technologies. Eligible applicants can receive funding up to $306,872 for Phase I and $2,045,816 for Phase II, with a submission deadline of April 5, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PA-24-246.html.
    Investigator-Initiated Research in Genomics and Health Equity (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Investigator-Initiated Research in Genomics and Health Equity (R21 Clinical Trial Optional)" aimed at supporting small-scale research projects that enhance health equity through genomic research. The initiative seeks to develop innovative approaches and metrics to ensure the equitable application of genomics in improving health outcomes for U.S. populations, particularly focusing on historically underrepresented groups in biomedical research. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofit organizations, and state governments, with funding available up to $200,000 annually for a maximum of two years. Interested parties should submit their applications by July 8, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage for more details at https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-23-018.html.
    Investigator-Initiated Research in Genomics and Health Equity (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Investigator-Initiated Research in Genomics and Health Equity" (RFA-HG-23-017), aimed at promoting health equity through innovative genomic research. This initiative encourages applicants to propose research that enhances the understanding and application of genomics across diverse U.S. populations, with a particular focus on engaging underrepresented groups and incorporating a Plan for Enhancing Diverse Perspectives (PEDP). The NIH plans to commit significant funds, with a maximum budget of $500,000 in direct costs per year for projects lasting four to five years, and applications are due by July 8, 2025. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to review the full announcement at NIH Grants.
    Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities," aimed at supporting U.S. small businesses in developing innovative technologies, products, or services that address health disparities among minority populations. Eligible applicants are encouraged to propose solutions that enhance healthcare delivery, promote health-seeking behaviors, and overcome barriers in minority health, with funding available through the Small Business Innovation Research (SBIR) program for both Phase I and II grants. This initiative underscores the government's commitment to advancing health equity and leveraging small business innovation to tackle significant healthcare challenges faced by underserved communities. Applications are due by December 10, 2026, and interested parties can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Addressing Health Inequities in Clinical Diagnostics (R41/R42 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Addressing Health Inequities in Clinical Diagnostics" grant, aimed at encouraging small businesses to develop innovative clinical diagnostic tools that address health disparities. Applicants are required to identify specific issues within existing clinical diagnostics that contribute to health inequities, particularly affecting underrepresented populations, and propose viable solutions to enhance equitable access to quality healthcare. This funding opportunity, which falls under the R41/R42 grant mechanism, does not support clinical trials and emphasizes the importance of stakeholder engagement from health disparity populations. Interested applicants can find more information and submit their proposals by the ongoing deadlines, with the final submission date set for January 5, 2027. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-157.html.